EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
OCT 2024
-
EDITION 6
-
TABLES 123
-
REGIONS 12
-
SEGMENTS 6
-
PAGES 192
-
US$ 4950
-
MCP15128
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
© Copy rights Global Industry Analysts, Inc., USA. www.strategyr.com All Rights Reserved.
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
Global Systemic Psoriasis Therapeutics Market to Reach US$50.1 Billion by 2030
The global market for Systemic Psoriasis Therapeutics estimated at US$29.2 Billion in the year 2023, is expected to reach US$50.1 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2023-2030. TNF Inhibitors, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$18.5 Billion by the end of the analysis period. Growth in the Interleukin Inhibitors segment is estimated at 8.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$7.9 Billion While China is Forecast to Grow at 7.5% CAGR
The Systemic Psoriasis Therapeutics market in the U.S. is estimated at US$7.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.
Global Systemic Psoriasis Therapeutics Market - Key Trends and Drivers Summarized
How Are Advances in Psoriasis Treatments Addressing Systemic Conditions?
Systemic psoriasis therapeutics have transformed the management of psoriasis by targeting the underlying causes of the disease rather than just the symptoms. Systemic treatments are typically used for patients with moderate to severe psoriasis and include biologics, small molecule drugs, and systemic immunosuppressants. Biologics, which target specific components of the immune system responsible for inflammation, have gained significant traction due to their efficacy and ability to manage the condition long-term. With advancements in understanding the genetic and immunological underpinnings of psoriasis, newer biologics and other targeted therapies are providing better outcomes and improving patients` quality of life.
What Technological Innovations Are Driving Psoriasis Treatment?
Technological advancements, particularly in biotechnology and pharmacogenomics, are reshaping the landscape of systemic psoriasis therapeutics. Biologics, which are genetically engineered proteins derived from human genes, have been developed to specifically inhibit the immune pathways involved in psoriasis, such as TNF-alpha inhibitors and interleukin inhibitors. Additionally, small molecule drugs targeting specific proteins within immune cells are emerging as a promising treatment option. Advances in precision medicine are also enabling more personalized treatment plans, as genetic and biomarker profiling allow physicians to identify the most effective therapies for individual patients based on their genetic predispositions.
Which Patient Segments and Markets Are Driving Demand for Systemic Psoriasis Therapies?
The demand for systemic psoriasis treatments is growing across various patient demographics and geographies, with a significant uptick in developed markets such as North America and Europe. However, the increasing incidence of psoriasis in emerging markets in Asia-Pacific, driven by factors such as rising urbanization, lifestyle changes, and environmental triggers, is also contributing to market expansion. Additionally, systemic treatments are becoming the preferred option for patients with moderate to severe psoriasis who have not responded well to topical or phototherapy treatments. The rise of biologics and the approval of newer therapies have significantly expanded the treatment options available to these patients.
What Is Fueling the Growth of the Systemic Psoriasis Therapeutics Market?
The growth in the systemic psoriasis therapeutics market is driven by several factors, including the increasing prevalence of psoriasis, particularly in urban areas, and the growing availability of advanced biologics and small molecule drugs. The expanding adoption of biologics, improved diagnostic capabilities, and greater awareness of the condition among healthcare providers and patients are key growth drivers. Additionally, the significant investments by pharmaceutical companies in R&D to develop more effective and safer therapies are driving innovation in this space. Favorable regulatory environments, government initiatives for better patient care, and advancements in personalized medicine further support the market`s growth.
SELECT PLAYERS
AbbVie Inc.; Amgen Inc.; Biogen Idec; Celgene Corporation; Eli Lilly and Company; Janssen Biotech, Inc.; Novartis AG; Pfizer Inc.; Stiefel Laboratories, Inc.; Takeda Pharmaceutical Company Limited
SEGMENTS
» Drug Class (TNF Inhibitors, Interleukin Inhibitors, Other Drug Classes) » Route of Administration (Parenteral, Oral, Topical)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Global Economic Update |
| Systemic Psoriasis Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 38 Players Worldwide in 2024 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Growing Prevalence of Psoriasis Propels Demand for Systemic Therapeutics |
| Advancements in Biologics Drive Growth in Psoriasis Treatment Market |
| Increased Focus on Personalized Medicine Expands Addressable Market for Psoriasis Therapies |
| Development of Targeted Immunomodulatory Drugs Spurs Market Growth |
| Rising Awareness and Diagnosis Rates of Psoriasis Strengthen Business Case for Therapeutics |
| Emergence of Biosimilars in Psoriasis Treatment Accelerates Market Access |
| Increasing Availability of Oral Systemic Therapies Drives Adoption Among Patients |
| Advances in Monoclonal Antibodies and Small Molecule Drugs Generate Market Demand |
| Growing Focus on Long-Term Remission Solutions Drives Innovation in Psoriasis Therapeutics |
| Expansion of Telemedicine and Digital Health Platforms Strengthens Market Access |
| Global Aging Population and Rising Healthcare Spending Drive Market Growth |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Systemic Psoriasis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
| World Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Systemic Psoriasis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Systemic Psoriasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for TNF Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for TNF Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for TNF Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Interleukin Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
| USA Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| USA Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| USA 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| USA Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| USA Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| USA 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Canada Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Canada 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Canada Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Canada Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Canada 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| JAPAN |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
| Japan Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Japan Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Japan 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Japan Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Japan Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Japan 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| CHINA |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
| China Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| China Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| China 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| China Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| China Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| China 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| EUROPE |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
| Europe Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
| Europe Historic Review for Systemic Psoriasis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Europe 16-Year Perspective for Systemic Psoriasis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030 |
| Europe Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Europe Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Europe 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Europe Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Europe Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Europe 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| FRANCE |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
| France Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| France Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| France 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| France Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| France Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| France 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| GERMANY |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
| Germany Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Germany Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Germany 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Germany Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Germany Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Germany 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Italy Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Italy 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Italy Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Italy Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Italy 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| UNITED KINGDOM |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
| UK Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| UK Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| UK 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| UK Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| UK Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| UK 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of Europe Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of Europe 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of Europe Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of Europe 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| ASIA-PACIFIC |
| Systemic Psoriasis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Asia-Pacific 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Asia-Pacific 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of World Historic Review for Systemic Psoriasis Therapeutics by Drug Class - TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of World 16-Year Perspective for Systemic Psoriasis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors, Interleukin Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030 |
| Rest of World Recent Past, Current & Future Analysis for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
| Rest of World Historic Review for Systemic Psoriasis Therapeutics by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
| Rest of World 16-Year Perspective for Systemic Psoriasis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2014, 2024 & 2030 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.